Punit P Seth
Overview
Explore the profile of Punit P Seth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
3064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duchamp E, Vasquez G, Firoozi N, Freestone G, Oestergaard M, Seth P, et al.
RSC Adv
. 2024 Jul;
14(33):23583-23591.
PMID: 39070250
Therapeutic oligonucleotides are chemically modified to enhance their drug-like properties - including binding affinity for target RNA. Many nucleic acid analogs that enhance RNA binding affinity constrain the furanose sugar...
2.
Rajasekaran T, Freestone G, Galindo-Murillo R, Lugato B, Gaus H, Migawa M, et al.
J Org Chem
. 2023 Mar;
88(6):3599-3614.
PMID: 36857642
We recently described a chemical strategy to pre-organize a trinucleotide subunit in a conformation suitable for Watson-Crick base pairing for modulating the binding kinetics of single-stranded oligonucleotides (ONs) using bis-phosphonate...
3.
Finicle B, Eckenstein K, Revenko A, Anderson B, Wan W, McCracken A, et al.
Nucleic Acids Res
. 2023 Feb;
51(4):1583-1599.
PMID: 36727438
Inefficient endosomal escape remains the primary barrier to the broad application of oligonucleotide therapeutics. Liver uptake after systemic administration is sufficiently robust that a therapeutic effect can be achieved but...
4.
Zhang L, Liang X, De Hoyos C, Migawa M, Nichols J, Freestone G, et al.
Nucleic Acid Ther
. 2022 Jul;
32(5):401-411.
PMID: 35861704
Antisense oligonucleotides (ASOs) that mediate RNA target degradation by RNase H1 are used as drugs to treat various diseases. Previously we found that introduction of a single 2'--methyl (2'-OMe) modification...
5.
Kuo C, Nikan M, Yeh S, Chappell A, Tanowitz M, Seth P, et al.
Nucleic Acid Ther
. 2022 May;
32(4):300-311.
PMID: 35612431
We evaluated the potential of AGTR1, the principal receptor for angiotensin II (Ang II) and a member of the G protein-coupled receptor family, for targeted delivery of antisense oligonucleotides (ASOs)...
6.
Rajasekaran T, Freestone G, Galindo-Murillo R, Lugato B, Rico L, Salinas J, et al.
J Am Chem Soc
. 2022 Jan;
144(4):1941-1950.
PMID: 35041415
The binding affinity of therapeutic oligonucleotides (ONs) for their cognate RNA is determined by the rates of association () and dissociation (). Single-stranded ONs are highly flexible and can adopt...
7.
Mukherjee P, Aksamitiene E, Alex A, Shi J, Bera K, Zhang C, et al.
Nucleic Acid Ther
. 2021 Nov;
32(3):163-176.
PMID: 34797690
Antisense oligonucleotides (ASOs), a novel paradigm in modern therapeutics, modulate cellular gene expression by binding to complementary messenger RNA (mRNA) sequences. While advances in ASO medicinal chemistry have greatly improved...
8.
Vasquez G, Migawa M, Wan W, Low A, Tanowitz M, Swayze E, et al.
Nucleic Acid Ther
. 2021 Oct;
32(1):40-50.
PMID: 34698585
The phosphorothioate (PS) linkage in an essential component of therapeutic oligonucleotides. PS in the DNA region of gapmer antisense oligonucleotides (ASOs) supports RNaseH1 activity and enhances nuclease stability. PS also...
9.
Anderson B, Freestone G, Low A, De-Hoyos C, Iii W, Ostergaard M, et al.
Nucleic Acids Res
. 2021 Aug;
49(16):9026-9041.
PMID: 34417625
The PS modification enhances the nuclease stability and protein binding properties of gapmer antisense oligonucleotides (ASOs) and is one of very few modifications that support RNaseH1 activity. We evaluated the...
10.
Nagata T, Dwyer C, Yoshida-Tanaka K, Ihara K, Ohyagi M, Kaburagi H, et al.
Nat Biotechnol
. 2021 Aug;
39(12):1529-1536.
PMID: 34385691
Achieving regulation of endogenous gene expression in the central nervous system (CNS) with antisense oligonucleotides (ASOs) administered systemically would facilitate the development of ASO-based therapies for neurological diseases. We demonstrate...